Brammer Bio, a cell and gene therapy contract development and manufacturing organization (CDMO), says it is on-track to complete the establishment of commercial-ready gene therapy manufacturing capacity in Cambridge, MA, in the second half of 2017. This follows the January 1, 2017 acquisition of Biogen’s biologics manufacturing facility in Cambridge and distribution center in Somerville, MA, that included the on-boarding of an experienced team of 100 employees. Further, Brammer completed a...